Key Takeaways VKTX shares rose 34% in three months on momentum around its investigational obesity drug VK2735.Viking hit fast enrollment milestones for phase III VANQUISH-1 and phase II VENTURE-Oral studies.Viking is also enrolling the VANQUISH-2 study, targeting completion of recruitment in early 2026.Shares of Viking Therapeutics (VKTX) have surged 34% in the past three months, primarily driven by positive investor expectations around its investigational obesity drug, VK2735.Last month, Viking announced t ...